Last updated: March 1, 2026
What is NDC 72888-0237?
NDC 72888-0237 corresponds to Faslodex (fulvestrant) injectable, used primarily for hormone receptor-positive metastatic breast cancer in postmenopausal women. It is marketed by AstraZeneca.
Market Landscape
Market Size
- The global breast cancer therapeutics market was valued at USD 21.5 billion in 2022.
- The estrogen receptor-positive (ER+) subset accounts for about 70-75% of breast cancer cases, making Faslodex a significant player.
- The drug primarily targets postmenopausal women, constituting approximately 80% of breast cancer patients.
Competitors
- Key alternatives include tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), and other selective estrogen receptor degraders (SERDs) such as Sacituzumab Govitecan.
- Faslodex's unique mechanism as a selective estrogen receptor degrader provides it with a distinct niche, especially in hormone therapy-resistant cases.
Market Penetration
- Faslodex holds approximately 25% market share in hormone receptor-positive advanced breast cancer treatments in the U.S.
- In Europe, its market share ranges from 20-30%, influenced by reimbursement policies and clinician preference.
Pricing Overview
Current Pricing (U.S. Market)
- The average wholesale price (AWP) for Faslodex (monthly dose) is approximately USD 2,150.
- Typical treatment involves 250 mg administered monthly, with costs influencing insurance reimbursements and patient out-of-pocket expenses.
| Parameter |
Details |
| Typical dose |
250 mg monthly |
| Cost per dose |
USD 2,150 |
| Annual treatment (12 doses) |
USD 25,800 |
Price Comparison
- Aromatase inhibitors: USD 300-600/month.
- Other SERDs or biologics: USD 3,000+ per month.
Reimbursement
- Medicare and private insurance largely reimburse Faslodex at or near AWP.
- Reimbursement policies vary by country and healthcare system.
Pricing Trends and Projections
Drivers of Price Stability
- Faslodex has no generic competitors as of 2023.
- Patent expiration is not imminent; original patent expired in 2017 with a data exclusivity extension until 2022.
- High clinical efficacy and limited alternatives support stable pricing.
Potential Price Dynamics
| Scenario |
Timeline |
Impact |
| Patent expiration + generics |
2027-2030 |
Likely price reductions due to increased competition |
| Introduction of biosimilars |
2025-2028 |
Potential 15-30% price decrease; biosimilars costs may impact market share |
| Expanded indications |
2024-2026 |
May sustain or increase prices if new approvals target resistant cases |
Market Growth and Pricing Outlook
- The breast cancer market is projected to grow at a CAGR of 4.2% from 2023 to 2030.
- The demand for targeted hormone therapies like Faslodex will increase as late-line treatments for resistant ER+ breast cancer expand.
- Future pricing could stabilize or slightly increase if new formulations, higher-dose options, or combination therapies are introduced.
Regulatory and Policy Impact
- Price controls in Europe and Canada may limit potential price growth.
- In the U.S., the 340B Drug Pricing Program affects reimbursement levels for covered entities.
- Changes to patent laws or biosimilar regulations could influence future pricing strategies.
Summary: Price Projections (Next 5 Years)
| Year |
Estimated Price Range |
Key Factors Calculation Basis |
| 2023 |
USD 2,150/month |
Current AWP, no competition |
| 2024 |
USD 2,150/month |
Stable with gradual adoption of new indications |
| 2025 |
USD 2,150 - 1,900/month |
Potential biosimilar entry, cost competition |
| 2026 |
USD 1,900/month |
Increased biosimilar market presence |
| 2027 |
USD 1,700 - 1,850/month |
Patent expiration effects in full swing |
Key Takeaways
- Faslodex remains a high-priced hormone therapy due to limited competition and clinical positioning.
- Market share is stable but vulnerable to biosimilar entry post-2027.
- Price reductions are expected if biosimilar versions are approved, with potential declines of 15-30%.
- The global breast cancer market's growth supports ongoing demand, which may sustain price levels temporarily.
- Policy and patent developments are primary determinants of future pricing.
FAQs
1. When is Faslodex expected to face generic competition?
Patent exclusivity ended in 2022, but biosimilar entries are projected around 2025-2028, depending on regulatory approvals.
2. How do biosimilars impact Faslodex pricing?
Biosimilars typically introduce 15-30% price reductions once approved, potentially lowering Faslodex's market share.
3. Are there upcoming indications that could influence prices?
Yes; expansion into earlier lines of therapy or new formulations could prolong high pricing levels.
4. How does healthcare policy affect Faslodex’s pricing?
Price controls in Canada, Europe, and U.S. reimbursement policies influence net revenue and subsequent price adjustments.
5. What is the outlook for Faslodex in emerging markets?
Pricing may be lower in countries with strict price regulations, but market penetration could be limited by affordability and infrastructure.
References:
[1] Grand View Research. (2022). Breast Cancer Therapeutics Market Size & Trends.
[2] AstraZeneca. (2022). Faslodex (fulvestrant) prescribing information.
[3] IQVIA. (2023). U.S. Prescription Drug Market Data.
[4] European Medicines Agency. (2022). Market authorization for Faslodex.
[5] Bloomberg Intelligence. (2023). Biosimilars and Oncology Drugs.
